He Promised '10 Peptides to Superhuman.' We Counted 12 — and Checked the Rest.

Jacob Nachinson's 90-day experiment is the peptide influencer genre in its most polished form. The substances are real. The evidence isn't: no bloodwork, an unmeasurable centerpiece claim, a flagship dose stated two different ways, and basic muscle biology backwards — all funneling into a clinic he co-owns.

Jacob Nachinson is not a doctor, and he says so. He is a Tampa entrepreneur with roughly 350,000 Instagram followers, a YouTube channel managed by a professional growth agency — titles, thumbnails and strategy included — and a sideline he mentions less plainly: he is a co-founder of Overtime Men’s Health, a telehealth clinic that sells testosterone and peptide protocols in all 50 states. His video “I Injected 10 Peptides for 90 Days (Superhuman Experiment)” is the genre’s standard product at its most polished: a comic-book promise, a lab-coat structure, ninety days of check-ins, and a full protocol released at the end for viewers who want to, in his words, replicate it for themselves.

We checked it the way we check everything: transcript first, then the record. Here is the honest summary before the detail — he is not making the substances up. He is making the evidence up. Watch the video with our scorecard.

First, the credit — some of this is real

A fair check starts with what survives one, because several of his compounds are not the snake oil of caricature:

SS-31 is elamipretide — a real drug. On September 19, 2025, the FDA granted it accelerated approval (brand name Forzinity, from Stealth BioTherapeutics) — the first treatment ever approved for Barth syndrome, a rare genetic disease. That approval is real.
ARA-290 (cibinetide) has genuine human data — small Phase 2 trials in sarcoidosis small-fiber neuropathy, roughly 150–220 subjects in total, with corneal nerve-regrowth signals. Real science, published and peer-reviewed.
Thymosin alpha-1 is a legitimate drug somewhere — as Zadaxin, approved in more than 35 countries for hepatitis B and vaccine-support uses.
He discloses the two facts a lesser production would bury: that he is not a doctor, and that he is on testosterone replacement therapy. Both disclosures are in the video. Our complaint is not that they’re absent — it’s what he does with them: nothing. Neither one is ever allowed to qualify a conclusion.

Hold those credits in mind. They are what makes the rest of this necessary — borrowed credibility is the genre’s engine, and these three compounds are the collateral.

The bloodwork that never appears

The video’s scientific backbone, invoked repeatedly, is laboratory monitoring: “I’m getting blood tests all along the way.” Ninety days of filming later, the experiment closes with this sentence: “I still have to take my remaining blood work.”

No lab result — not one value — appears in the video. The description contains no results, no lab report, no data link. It contains exactly one link in its opening line: his own clinic’s membership page, advertising that “all my bloodwork and protocols are done through” Overtime Men’s Health, “memberships with bloodwork included, available now in all 50 states.”

Read that structure carefully, because it is the whole business in miniature. The bloodwork functions in the video as a promise of rigor. It functions in the description as a product. The numbers were never the point — the membership was. An experiment whose only objective instrument is a wristband, and whose promised labs are perpetually pending, is not an experiment with missing paperwork. The paperwork was the product being sold.

The count doesn’t survive his own video

The title promises 10 peptides. Counting only the injectables he names across the four phases: SS-31, KPV, ARA-290, BPC-157, TB-500, NAD+, FOXO4-DRI, epitalon, pinealon, thymosin alpha-1, MOTS-c — eleven. Plus, mid-video, a twelfth substance enters the experiment by accident (below). (Three further products in the purge phase — PQQ, urolithin A, spermidine — are oral supplements, not peptides, and we don’t count them against him.)

You can only reach “10” by quietly excluding one — NAD+ is the usual candidate, since calling a coenzyme a peptide is itself a stretch — and the count then still ignores the accident. When a video’s title cannot survive contact with its own contents, that is not a rounding choice. That is the marketing department outranking the lab notebook, in a video whose entire premise is the lab notebook.

The flagship dose, stated two ways — the sloppiness finding

We do not publish protocols, his or anyone’s. We quote the following two figures for one reason only: they contradict each other, inside a single video, about its flagship compound.

In the day-1 segment, SS-31 is “roughly 15 mg a day,” with a stated total of “200 mg.” In the final recap, the same compound is “12.5 milligrams a day.” And the first version doesn’t reconcile internally either: 15 a day across the stated 20-day phase is 300, not 200.

Three numbers; no two agree. This matters beyond pedantry. The video’s closing act — the payload the first eighteen minutes exist to deliver — is a written protocol presented as the distilled product of ninety days of careful self-measurement. A presenter who cannot keep his flagship compound’s amount straight across one video assembled that protocol with the same care. Viewers are invited to put it in their bodies anyway.

The claim no instrument on Earth could check

Phase two is built on FOXO4-DRI, a senolytic peptide from a striking 2017 mouse study (Baar et al., Cell) in which it cleared senescent cells and restored fur density, fitness and kidney markers in mice — established, in that study, by dissecting tissue.

Nachinson concedes on camera that FOXO4-DRI has “no human trials in history” — true; nine years after the founding paper there is no registered, published, or completed human trial of it. He then reports that it destroyed “nearly all” the senescent cells in his liver, lung, kidney, heart, and muscle.

There is no validated clinical biomarker, scan, or blood test for organ senescent-cell burden in a living human. None exists. He measured nothing, because nothing measurable exists. This is the video’s purest specimen: a claim constructed so that no evidence could ever embarrass it, attached to a compound he nonetheless includes in the protocol he releases for replication. A substance that has never been administered to a human being in any recorded trial is being handed to his audience as a finished recipe step.

The same pattern repeats at smaller scale. Epitalon’s telomere claim descends from one research institute’s program; the most-cited long-term human study in that literature used epithalamin, a crude pineal extract — not the synthetic epitalon he injected — and no human trial has ever measured telomere lengthening in a treated person. He measured no telomeres. His hair-thickening speculation is extrapolated, by his own framing, from mouse fur. Pinealon’s entire evidence base is cell cultures, rodent models and computer simulations from the same institute family; the one study that tested it on pineal cells came back negative. MOTS-c has no completed published human trial; the FDA has stated it identified no human exposure data for MOTS-c products. His “dopamine reset” narrative about it is an anecdote recorded while he was also overhauling his sleep, sunlight, phone use and training.

The approval that doesn’t say what he needs it to say

Since he leans on SS-31’s legitimacy, the fine print belongs on the record. Elamipretide’s approval is narrow and accelerated: improving muscle strength in Barth syndrome patients of at least 30 kg, based on an intermediate endpoint. The randomized Barth trial behind it (TAZPOWER, n=12) missed its primary endpoints — six-minute walk distance and fatigue. Elamipretide’s larger trials in heart failure, primary mitochondrial myopathy and dry eye disease all missed their primary endpoints too, and confirmatory benefit remains unproven.

The approval validates a rare-disease drug under specialist care, for a disease whose patients have no alternative. It validates nothing about a healthy man injecting gray-market material labeled “SS-31” — which is not Forzinity, was not made by Stealth, and passed through no one’s quality system — for mitochondrial “repair,” a benefit never demonstrated in any population that has ever existed.

ARA-290’s reality is sadder and simpler: real Phase 2 science, then the developer, Araim Pharmaceuticals, ceased operations; the last trial was terminated because the drug supply expired; there has been no human data since roughly 2017–2020 and no approval anywhere. A narrow nerve-pain signal in sick patients, a decade stale, is recruited in this video as a “repair phase” for a healthy lifter. And thymosin alpha-1’s foreign approvals cover hepatitis B and vaccine support — while the FDA’s advisory committee voted 17–4 against adding it to the US compounding list in December 2024, and no regulator on Earth lists “clearing debris between peptide phases” among its uses.

Basic muscle biology, backwards

In the video’s science framing, Nachinson explains his phase design with an AMPK-versus-mTOR story, and states that “mTOR is catabolic to muscle growth.”

mTOR signaling is the central anabolic pathway in muscle biology. It is the mechanism that drives muscle protein synthesis — the thing every muscle-building claim in the video ultimately depends on. This is not a contested frontier or a simplification for a lay audience. It is textbook, and it is inverted, delivered with complete confidence, in the section of the video that exists to establish that the presenter understands the mechanisms he is manipulating in his own body and prescribing, in effect, to his viewers.

The mood ring, and the variable he mentioned once

His quantitative proof of success is the Whoop wearable: he “cracked the code on Whoop recovery.” Whoop’s underlying heart-rate-variability sensing at rest is legitimately decent. Its Recovery score, however, is a proprietary composite — a black-box blend whose formula is undisclosed and which has never been validated against any gold-standard measure of recovery or next-day performance. In the closest independent look, the raw HRV tracked stress while the composite score tracked nothing identifiable. HRV also moves with sleep, alcohol abstinence, illness, training load — and expectation.

Which brings us to the variable that swallows the experiment whole. He ran these ninety days on testosterone replacement therapy: an anabolic, energizing hormone with documented effects on muscle, recovery, mood and libido — which is to say, on essentially every outcome the video claims. His own benchmark for success is telling: “best results since I very first started TRT.” Layered on top: phase-by-phase diet changes (including a deliberate low-carbohydrate “purge” phase with no training, which by itself explains the celebrated 10–15 pound scale drop), restructured training, improved sleep, morning sunlight, reduced phone use, and the momentum of a man narrating his recovery from heavy drinking and drug use. He acknowledges placebo exactly once — “whether it’s the peptide or placebo or whatever I’m enjoying it” — and never revisits it.

Could every outcome he reports have occurred if not one peptide molecule did anything? Yes — comfortably, with room to spare. That does not prove the peptides did nothing. It proves the video cannot distinguish, and a video that cannot distinguish has no business concluding — let alone publishing a protocol.

The most honest moment in the video

Mid-experiment, told casually, as a joke: he injected the wrong vial. Reaching for MOTS-c, he injected melanotan-2 — a tanning drug with its own documented emergency record (priapism requiring emergency care, a published ICU case of muscle breakdown and kidney injury; our melanotan II page carries the file) — because the gray-market vials in a multi-compound self-experiment look alike.

In a production that took safety seriously, this is the moment the premise visibly fails: one man, a dozen look-alike unregulated vials, no verification step, and an error he survived by luck of compound rather than by design. In this production it is a punchline — after which the video continues, undisturbed, toward a finale inviting thousands of viewers to replicate the setup in their own homes.

Where the video actually ends

Not with data. The description’s first line is a membership advertisement for Overtime Men’s Health. Across the channel, video descriptions carry an affiliate-tracked application link — on the EonPro clinic platform, bearing his personal code — inviting viewers to “have my medical team build your custom peptide protocol.” The channel runs cash giveaways for follows and reposts, including gift cards for his own clinic. The titles and thumbnails are produced by an agency that advertises the growth in subscribers and views it manufactures.

None of this is hidden, exactly. It is simply never stated: nowhere does the video say, in words, “the experiment you are watching is content marketing for a clinic I co-own, whose memberships fund it.” The conflict of interest is disclosed the way a terms-of-service discloses — structurally present, functionally invisible. His opening disclaimer says he is not a doctor. The honest disclaimer would say what he is.

The bottom line

Audit the whole production and it resolves into five piles. About a fifth is real substances with real-but-early science, used in ways that science never tested. About a quarter is unmeasurable claims — senescent cells cleared from five organs, telomeres lengthened, mitochondria repaired — chosen, consciously or not, precisely because no measurement exists to contradict them. The largest share, roughly a third, is confounded anecdote: testosterone, diet phases, training changes, sleep repair and recovery momentum fully account for every result reported. About a tenth is demonstrably wrong or self-contradictory: the title’s count, the flagship dose stated two ways with broken arithmetic, a core mechanism inverted, bloodwork invoked as ongoing and admitted at the end to be outstanding. And the final tenth is machinery: the affiliate link, the membership ad, the giveaway funnel, the agency-optimized packaging — small as a share of runtime, and load-bearing, because it is what the other ninety percent is for.

Jacob Nachinson is not making the substances up — he’s making the evidence up. The vials are real; the “experiment” isn’t. It is an advertisement for Overtime Men’s Health with a disclaimer where the conscience should be — and the most dangerous thing in it is not any compound. It is the closing invitation to replicate, issued by a man who, in the same video, could not keep his own vials straight.